What To Avoid And Pearls Of Wisdom In A Partnered Drug Development Model

Rob Wright, chief editor of Life Science Leader, conducted an executive virtual roundtable with Pamela Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics, a clinical-stage oncology company; and Dara Lockert, founder and executive director of Spannerwerks, a life science industry consultancy (view full video here). In this concluding section, Contag and Lockert provide advice for CEOs on things to avoid when outsourcing clinical trials, and parting pearls of wisdom to keep in mind when partnering for drug development. For more information on Contag’s approach to outsourcing, be sure to read, “A Small Biopharma’s View Of Working With CROs,” published in the July 2020 CRO Leadership Awards special supplement. You might also enjoy the feature article with Contag, “BioEclipse Therapeutics — More Than Just A Story Of Rebranding.”